Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma
- PMID: 16787112
- DOI: 10.2217/14796694.2.3.333
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma
Abstract
Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma. It has been used in both canine and human osteosarcoma to reduce pulmonary metastases, the most common pattern of treatment failure for sarcomas. L-MTP-PE has been well tolerated using the concept of biological cancer therapy during chemotherapy. The use of L-MTP-PE with ifosfamide is the best studied combination with single agent chemotherapy. This may represent a new treatment choice for osteosarcoma patients receiving ifosfamide. Such patients include those with a poor initial histological response to primary therapy and/or metastatic disease including pulmonary metastases. Reduction of side effects of L-MTP-PE, such as fever and/or flu-like symptoms, with ibuprofen has not reduced efficacy. Since improved symptom control is possible using drug combinations that are especially effective for delayed nausea, outpatient high-dose ifosfamide chemotherapy combined with L-MTP-PE may lead to a safe and effective therapy while maintaining the patients' quality of life.
Similar articles
-
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.Expert Rev Anticancer Ther. 2008 Feb;8(2):151-9. doi: 10.1586/14737140.8.2.151. Expert Rev Anticancer Ther. 2008. PMID: 18279055 Review.
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Hematol Oncol Clin North Am. 1995. PMID: 7490249 Review.
-
Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Adv Exp Med Biol. 2014. PMID: 24924182 Review.
-
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):181-93. doi: 10.1097/00002371-199504000-00007. J Immunother Emphasis Tumor Immunol. 1995. PMID: 7613644 Clinical Trial.
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.Am J Clin Oncol. 1995 Apr;18(2):93-9. doi: 10.1097/00000421-199504000-00001. Am J Clin Oncol. 1995. PMID: 7900714 Clinical Trial.
Cited by
-
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).BMC Cancer. 2022 Jun 8;22(1):629. doi: 10.1186/s12885-022-09697-9. BMC Cancer. 2022. PMID: 35672690 Free PMC article. Clinical Trial.
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566. Cancer. 2009. PMID: 19637348 Free PMC article. Clinical Trial.
-
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.Pediatr Blood Cancer. 2014 Feb;61(2):238-44. doi: 10.1002/pbc.24686. Epub 2013 Aug 31. Pediatr Blood Cancer. 2014. PMID: 23997016 Free PMC article.
-
Molecular biology and therapeutics in musculoskeletal oncology.J Bone Joint Surg Am. 2009 Mar 1;91(3):724-32. doi: 10.2106/JBJS.I.00012. J Bone Joint Surg Am. 2009. PMID: 19255238 Free PMC article. No abstract available.
-
The Current and Future Therapies for Human Osteosarcoma.Curr Cancer Ther Rev. 2013 Feb;9(1):55-77. doi: 10.2174/1573394711309010006. Curr Cancer Ther Rev. 2013. PMID: 26834515 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
